Drugs / M6229
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07285603 | Nov 2024 → Jun 2025 | — | Matisse Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05208112 | Apr 2022 → Sep 2023 | infectious disease with sepsis | A.P.J. Vlaar | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M6229 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07285603 ↗ |
| Route | Intravenous | “Continuous intravenous infusion of M6229” NCT05208112 ↗ |